‘What’s Really Important Is, What Are We Doing Next?’: Sandoz On Biosimilar Ambitions
Adalimumab, Denosumab, Natalizumab, And Aflibercept All Under Discussion
In the second part of Generics Bulletin’s exclusive interview with Sandoz’s global head for biosimilars, Peter Stenico, he discusses the company’s various near-term pipeline opportunities, as well as his expectations for LOE opportunities in the next decade.
